This study investigated the profile of long-term blood pressure (BP)-lowering medication in a population-based cohort, and whether treatment effects on BP control or risk of cardiovascular disease (CVD) differed between the types or patterns of BP-lowering regimes. In treated hypertensive patients, only 11.3% had a BPo140/90 mm Hg. Inadequate drug combination and underestimation of global risk score seemed to be the possible reasons for poor BP control. Neither CVD morbidity nor mortality showed any significant difference in relation to treatment types or patterns.
Beneficial effects of BP-lowering medication on preventing CVD are well established. Diuretics and b-blockers have been recommended as basic antihypertensive agents. 1 Newly developed pharmacologic BP-lowering agents provide additional choice. Little is known about the profile of long-term BPlowering medication in a community-based setting and the effects of different types of treatment on BP control or CVD risk.
This study is a part of the 'Malmö Diet and Cancer (MDC)' cohort, which is a population-based prospective study of middle-aged or older Swedish men and women (n ¼ 28 449) in Malmö area. 2 Of them, 3608 subjects received medical treatment for hypertension and were without history of cardiac event (CE) or stroke before baseline examination. A random 50% of participants who entered the MDC study between 1991 and 1994 were sampled for measurements of fasting blood lipids. This subgroup was used for estimation of global CVD risk. The ethical committee at Lund University approved the MDC study (LU 51-90). Each participant gave an informed consensus.
By using a mercury sphygmomanometer, BP was measured in the right arm in a lying position after 5 min rest at the screening centre. Control of BP was defined as BPo140/90 mm Hg. 1 According to the number of prescribed BP-lowering drugs, the patterns of treatment were classified as monotherapy (single drug), two-combined therapy and three or more combined therapy. In relation to the different drug agents, the single drugs were further grouped as older type (diuretics or bblockers) and new type (angiotensin converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs)).
Information concerning the socio-demographic characteristics and lifestyle factors (smoking status, alcohol consumption and physical activity during leisure time) was collected from the self-reported questionnaire. A history of diabetes mellitus and family (parents) history of CVD events were inquired in the questionnaire.
Incidence of first-ever CVD event (fatal or nonfatal CE or stroke) or CVD death was followed for a mean period of 7.4 years. The procedures have been described elsewhere. 3 A general linear model or logistic regression model was applied to compare the baseline characteristics and achieved BP levels between older and new monotherapies, and between pattern of treatment with adjustments for age and sex. A risk score was formulated to predict the risk of CEs according to age, sex, smoking, diabetes, BP, highdensity lipoprotein cholesterol and low-density lipoprotein cholesterol during 12 years follow-up. The formula was based on the risk equation from the 'Framingham Heart Study'. 4 The levels of risk were categorized as low (o10%), medium (10-20%) and high (420%). Cox-regression model was utilized to assess the association between risk of CVD and pattern of treatment with age-sex adjustment and covariate adjustment. All comparisons were twosided and a 5% level of significance was used.
In the total of 3608 treated hypertensive patients (1559 men, 2049 women), 67.4% were treated with monotherapy, 29.2% used two drugs and 3.4% used three or more drugs. Of those monotherapies, the main antihypertensive agents were b-blockers (n ¼ 1191), diuretics (n ¼ 504), ACE inhibitors (n ¼ 335) or CCBs (n ¼ 402). The most common two-combined regimen was diuretics and b-blockers (n ¼ 405, 47.8%). The mean treatment duration of BP-lowering medication at baseline visit was 10.177.6 years.
A BP o140/90 mm Hg was recorded in 11.3% of pharmacologic-treated hypertensive patients. Nearly half of patients still had a systolic BP level X160 mm Hg. There was no significant relationship between achieved BP control and patterns of therapies (Table 1) . Age-sex-adjusted systolic and diastolic BP levels were somewhat higher in the patients treated with a new single drug in comparison with the older single one.
In this cohort, the global risk score could be estimated in 654 treated hypertensive patients. Distribution of risk score in this sub-cohort was low (19%), medium (46%) and high risk (35%). Among patients treated with monotherapy, nearly 80% had a medium or high-risk score. The risk score showed no significant difference between patients with older or newer monotherapy (P ¼ 0.71), but risk score was significantly higher in patients with 2 or X3 drugs (P ¼ 0.002).
Among treated hypertensive patients, 341 firstever CVD events (175 CEs, 166 stroke) and 128 CVD death occurred during follow-up. With crude or covariate-adjusted Cox-regression analyses, the incidence of CVD events (CE or stroke) or CVD death had no significant relation to the types or patterns of BP-lowering therapy even though a 24% reduction of CVD morbidity was associated with multiple combined therapy (RR ¼ 0.76 (0.42-1.36)).
In the present community-based cohort, adequate BP control (o140/90 mm Hg) was only achieved in 11% of treated hypertensive patients. This is similar to other European studies. 5 It is suggested that inadequate drug treatment and underestimation of the global CVD risk may be the important reasons for poor BP control. In terms of treatment effects on CVD complications, no significant difference was found between conventional and newer types of monotherapies, or between monotherapy and combination therapy. The reasons for poor BP control have been widely discussed. In clinical practice, it is a well-known fact that more than two-thirds of hypertensive patients require at least two or more types of BPlowering drugs to achieve recommended BP target. The application of combined therapies has been stressed by the current guideline: if BP is more than 20/10 mm Hg above BP goal, consideration should be given to initiating therapy with two agents. 1 In this study, the combined therapy was only prescribed to one-third of patients (32.6%). Among those with monotherapy, the majority had a SBP X140 mm Hg. According to the criteria described f Two-combined and three or more-combined regimens.
Research Letter above, more than 40% of patients treated with monotherapy should be considered to receive a combination regime. Underestimation of global CVD risk is one crucial reason for poor BP control. 6 This is supported by our findings that nearly 80% of patients treated with monotherapy had a medium or high risk of developing CVD events in the future. It is possible that physicians manage hypertensive patients according to a simple BP-based examination rather than a more integrated approach based on global risk stratification. 7 In the past decade, prescription of conventional medication, especially diuretics, tended to decline because of newly developed pharmacological agents. However, the outcomes from randomized trials have, in general, failed to exhibit better effects of newer drugs compared with older ones on CVD protection. 8 Similar results were observed in the present population-based study. However, it has been demonstrated that new agents are more effective than conventional ones in preventing CVD risk in the patients who had concomitant left ventricular hypertrophy or diabetes. 9, 10 In nature, this study is an ongoing prospective observational survey. The outcomes on estimating drug efficacy may be limited by infrequency of BP measurements and confounding factors of individuals. However, the present study represented an outline of BP-lowering treatment in the community setting, which could not be acquired from the clinical trials where the highest risk individuals are usually excluded. In addition, the strength of observational study (long-term investigation, different patterns of treatment, etc.) could contribute to the topic of BP-lowering medication.
Some limitations are worth noting. Because the present study was observational and population based, it is not possible to separate the effects of treatment from factors associated with the indication of treatment. This is the main shortcoming of this study. Another limitation of this study was the shortage of information on compliance, dosage or alteration of regimens during follow-up period. Other studies have shown that a great proportion of discontinuation of treatment or change of agents occurred within the first year of treatment. 11 In this cohort, the majority of hypertensive patients had been treated for a long time. Therefore, adherence to therapy may be relatively stable. In addition, one BP reading value at a single visit may lead to an overestimation of the proportion with high BP and underestimation of BP control.
Overall, with long-term BP-lowering medication, recommended BP control was achieved only by 11.3% of hypertensive patients. Inadequate drug combination and underestimation of global risk score may be possible reasons for poor BP control. Neither CVD morbidity nor mortality showed any significant difference in relation to type of agents or to pattern of therapy. 
